Movement Alert｜Hansoh Pharmaceutical Falls 3.08% in Regular Trading, Broad Pharmaceutical Sector Weakness Drags Shares Lower

Market Focus07-17

On July 17, Hansoh Pharmaceutical fell 3.08% in regular trading, trading at HK$31.98/share, with turnover of approximately HK$98.43 million.

The decline came amid broad-based selling across the pharmaceutical sector. Within the Pharmaceuticals sector where Hansoh Pharmaceutical belongs, the overall sector weakened significantly. Among individual stocks, CSPC Pharma down 4.65%, SBP Group down 4.94%, Hengrui Pharma down 4.14%, Asymchem down 7.77%, Luye Pharma down 5.41%.

The pullback follows a series of positive catalysts in prior sessions, including the company's announcement on July 14 that its subsidiary Avere Therapeutics will merge into Nasdaq-listed NextCure via a full-stock transaction, alongside a global exclusive license for IL-23 receptor antagonist HS-20118 carrying up to US$2.3 billion in total deal value. The stock had risen over 3% on both July 15 and July 16 on those developments, suggesting some profit-taking may be compounding today's sector-driven weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178132863?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 10:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178132863","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hansoh Pharmaceutical Falls 3.08% in Regular Trading, Broad Pharmaceutical Sector Weakness Drags Shares Lower","media":"Market Focus","content":"<p><p>On July 17, Hansoh Pharmaceutical fell 3.08% in regular trading, trading at HK$31.98/share, with turnover of approximately HK$98.43 million.</p><p>The decline came amid broad-based selling across the pharmaceutical sector. Within the Pharmaceuticals sector where Hansoh Pharmaceutical belongs, the overall sector weakened significantly. Among individual stocks, CSPC Pharma down 4.65%, SBP Group down 4.94%, Hengrui Pharma down 4.14%, Asymchem down 7.77%, Luye Pharma down 5.41%.</p><p>The pullback follows a series of positive catalysts in prior sessions, including the company's announcement on July 14 that its subsidiary Avere Therapeutics will merge into Nasdaq-listed NextCure via a full-stock transaction, alongside a global exclusive license for IL-23 receptor antagonist HS-20118 carrying up to US$2.3 billion in total deal value. The stock had risen over 3% on both July 15 and July 16 on those developments, suggesting some profit-taking may be compounding today's sector-driven weakness.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hansoh Pharmaceutical Falls 3.08% in Regular Trading, Broad Pharmaceutical Sector Weakness Drags Shares Lower</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hansoh Pharmaceutical Falls 3.08% in Regular Trading, Broad Pharmaceutical Sector Weakness Drags Shares Lower\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-17 10:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 17, Hansoh Pharmaceutical fell 3.08% in regular trading, trading at HK$31.98/share, with turnover of approximately HK$98.43 million.</p><p>The decline came amid broad-based selling across the pharmaceutical sector. Within the Pharmaceuticals sector where Hansoh Pharmaceutical belongs, the overall sector weakened significantly. Among individual stocks, CSPC Pharma down 4.65%, SBP Group down 4.94%, Hengrui Pharma down 4.14%, Asymchem down 7.77%, Luye Pharma down 5.41%.</p><p>The pullback follows a series of positive catalysts in prior sessions, including the company's announcement on July 14 that its subsidiary Avere Therapeutics will merge into Nasdaq-listed NextCure via a full-stock transaction, alongside a global exclusive license for IL-23 receptor antagonist HS-20118 carrying up to US$2.3 billion in total deal value. The stock had risen over 3% on both July 15 and July 16 on those developments, suggesting some profit-taking may be compounding today's sector-driven weakness.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1178132863","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178132863","pubTimestamp":1784255232,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 17, Hansoh Pharmaceutical fell 3.08% in regular trading, trading at HK$31.98/share, with turnover of approximately HK$98.43 million.The decline came amid broad-based selling across the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"走势警报|豪森制药常规交易中下跌3.08%，制药板块整体疲软拖累股价走低","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On July 17, Hansoh Pharmaceutical fell 3.08% in regular trading, trading at HK$31.98/share, with turnover of approximately HK$98.43 million.The decline came amid broad-based selling across the pharmaceutical sector. Within the Pharmaceuticals sector where Hansoh Pharmaceutical belongs, the overall sector weakened significantly. Among individual stocks, CSPC Pharma down 4.65%, SBP Group down 4.94%, Hengrui Pharma down 4.14%, Asymchem down 7.77%, Luye Pharma down 5.41%.The pullback follows a series of positive catalysts in prior sessions, including the company's announcement on July 14 that its subsidiary Avere Therapeutics will merge into Nasdaq-listed NextCure via a full-stock transaction, alongside a global exclusive license for IL-23 receptor antagonist HS-20118 carrying up to US$2.3 billion in total deal value. The stock had risen over 3% on both July 15 and July 16 on those developments, suggesting some profit-taking may be compounding today's sector-driven weakness.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178132863","isCrawlerRequest":true}